Deakin University

File(s) under permanent embargo

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Version 2 2024-06-02, 22:43
Version 1 2023-06-20, 02:43
journal contribution
posted on 2024-06-02, 22:43 authored by V Yogendrakumar, L Churilov, PJ Mitchell, TJ Kleinig, N Yassi, V Thijs, T Wu, D Shah, P Bailey, HM Dewey, PMC Choi, A Ma, T Wijeratne, C Garcia-Esperon, G Cloud, RV Chandra, DJ Cordato, B Yan, G Sharma, PM Desmond, MW Parsons, GA Donnan, SM Davis, BCV Campbell, R Dowling, S Bush, R Scroop, M Simpson, M Brooks, Hamed AsadiHamed Asadi, T Ang, F Miteff, C Levi, E Rodrigues, H Zhao, F Ng, F Alemseged, P Salvaris, H Rice, L De Villiers, H Brown, K Redmond, D Leggett, J Fink, W Collecutt, T Kraemer, C Muller, A Coulthard, K Mitchell, J Clouston, K Mahady, D Field, B O'Brien, Ben ClissoldBen Clissold, A Clissold, L Bolitho, L Bonavia, A Bhattacharya, A Wright, A Mamun, F O'Rourke, J Worthington, A Wong, H Ma, T Phan, W Chong, LA Slater, M Krause, T Harrington, K Faulder, B Steinfort, C Bladin
Background and ObjectivesThe safety and efficacy of tenecteplase (TNK) in patients with tandem lesion (TL) stroke is unknown. We performed a comparative analysis of TNK and alteplase in patients with TLs.MethodsWe first compared the treatment effect of TNK and alteplase in patients with TLs using individual patient data from the EXTEND-IA TNK trials. We evaluated intracranial reperfusion at initial angiographic assessment and 90-day modified Rankin scale (mRS) with ordinal logistic and Firth regression models. Because 2 key outcomes, mortality and symptomatic intracranial hemorrhage (sICH), were few in number among those who received alteplase in the EXTEND-IA TNK trials, we generated pooled estimates for these outcomes by supplementing trial data with estimates of incidence obtained through a meta-analysis of studies identified in a systematic review. We then calculated unadjusted risk differences to compare the pooled estimates for those receiving alteplase with the incidence observed in the trial among those receiving TNK.ResultsSeventy-one of 483 patients (15%) in the EXTEND-IA TNK trials possessed a TL. In patients with TLs, intracranial reperfusion was observed in 11/56 (20%) of TNK-treated patients vs 1/15 (7%) alteplase-treated patients (adjusted odds ratio 2.19; 95% CI 0.28–17.29). No significant difference in 90-day mRS was observed (adjusted common odds ratio 1.48; 95% CI 0.44–5.00). A pooled study-level proportion of alteplase-associated mortality and sICH was 0.14 (95% CI 0.08–0.21) and 0.09 (95% CI 0.04–0.16), respectively. Compared with a mortality rate of 0.09 (95% CI 0.03–0.20) and an sICH rate of 0.07 (95% CI 0.02–0.17) in TNK-treated patients, no significant difference was observed.DiscussionFunctional outcomes, mortality, and sICH did not significantly differ between patients with TLs treated with TNK and those treated with alteplase.Classification of EvidenceThis study provides Class III evidence that TNK is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and sICH compared with alteplase in patients with acute stroke due to TLs. However, the CIs do not rule out clinically important differences.Trial Registration;









Minneapolis, MN







Publication classification

C1.1 Refereed article in a scholarly journal




American Academy of Neurology